Drug and Therapeutics Bulletin 2006;44:57-60; doi:10.1136/dtb.2006.44857
Copyright © 2006 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Statins for primary prevention in type 2 diabetes

At least 1 in 40 people in the UK have type 2 diabetes mellitus, and the prevalence is increasing.1 Such people are more likely than others to develop, and to die from, cardiovascular disease.2–7 Statin therapy helps to prevent cardiovascular disease events among patients at increased risk, with or without diabetes, and is standard treatment for patients needing secondary prevention.8–14 Here we discuss whether statins should be used routinely for primary prevention of cardiovascular disease in patients with type 2 diabetes irrespective of other risk factors.




This article has been cited by other articles:


Home page
 DTBHome page
Preconception care for women with diabetes
DTB, May 1, 2008; 46(5): 36 - 40.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2006 BMJ Publishing Group Ltd.